"Looks great Bear but has this not been released before in a different format?  Your comment please."

Yes, the SGLT2i synergy was one of the main highlights of the post-AHA corporate presentation on November 18.

https://www.resverlogix.com/upload/media_element/202/0fe84959b9a4/betonmace-post-aha-presentation-final.pdf

However, today's news release also included those patients on DPP4 inhibitors and suggested synergy with DPP4is too. It is worth noting that DPP4i by themselves have failed to show cardiovascular benefit in diabetics. But.......if apabetalone can synergize with DPP4i to elicit profound cardio benefit, then this creates a huge opportunity for DPP4i (and apabetalone)!

BDAZ